Compare DERM & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | VYGR |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 193.5M |
| IPO Year | 2021 | 2015 |
| Metric | DERM | VYGR |
|---|---|---|
| Price | $4.30 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $13.75 | ★ $14.89 |
| AVG Volume (30 Days) | 193.9K | ★ 976.4K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,858,000.00 | $10,135,000.00 |
| Revenue This Year | $25.29 | N/A |
| Revenue Next Year | $50.00 | $129.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $1.68 |
| 52 Week High | $9.56 | $5.19 |
| Indicator | DERM | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 37.90 |
| Support Level | $4.31 | N/A |
| Resistance Level | $5.50 | $2.29 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 18.50 | 31.71 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.